Join Now

Yearly Archives: 2025

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

By Natalie Themm | Published January 9, 2025

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Posted in BioUtah News | Tagged | Comments Off on Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

By Natalie Themm | Published January 9, 2025

MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

Posted in BioUtah News | Tagged | Comments Off on MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay

M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

By Natalie Themm | Published January 9, 2025

Trial underscores IROS’s commitment to developing innovative therapies for unmet medical needs

Posted in BioUtah News | Tagged | Comments Off on M42’s IROS and Halia Therapeutics launch clinical study on obesity treatment in the UAE

ARUP Offers New Assay To Detect Influenza A (H5) Virus

By admin | Published January 3, 2025

SALT LAKE CITY, January 3, 2025—ARUP Laboratories today launched a new assay for the detection and subtyping of influenza A (H5) virus. This test will aid in the evaluation of individuals who may have been exposed to highly pathogenic avian influenza (HPAI) A virus, also known as H5N1 or bird flu. In early 2024, an outbreak […]

Posted in BioUtah News | Comments Off on ARUP Offers New Assay To Detect Influenza A (H5) Virus

Sethera Therapeutics Completes First Funding Round

By Natalie Themm | Published January 2, 2025

Sethera Therapeutics Completes First Funding Round

Posted in BioUtah News | Tagged | Comments Off on Sethera Therapeutics Completes First Funding Round

Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

By Natalie Themm | Published January 2, 2025

Data from Dual-Acting Oral Biologic Show Promising Safety and Efficacy Profile

Posted in BioUtah News | Tagged | Comments Off on Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis

CancerVax Passes First Test with Flying Colors

By Natalie Themm | Published January 2, 2025

Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

Posted in BioUtah News | Tagged | Comments Off on CancerVax Passes First Test with Flying Colors

Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

By Natalie Themm | Published January 2, 2025

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients.

Posted in BioUtah News | Tagged | Comments Off on Merit Medical Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

A Special Thanks To Our Legacy and Platinum Elite Members